Full Text Full Text (PDF) CME: Take the course for this article: AJP CME Course for August 2008: Selective Muscarinic Receptor Agonist Xanom... Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Shekhar, A. Articles by Felder, C. C. Search for Related Content PubMed Citation Articles by Shekhar, A. Articles by Felder, C. C. Neurotransmitters Atypical Neuroleptics Schizophrenia Spectrum Disorders Related Articles

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

OBJECTIVE: There are significant unmet needs in the treatment of schizophrenia, especially for the treatment of cognitive impairment, negative syndrome, and cognitive function. Preclinical data suggest that agonists with selective affinity for acetylcholine muscarinic receptors provide a potentially new mechanism to treat schizophrenia. The authors studied xanomeline, a relatively selective muscarinic type 1 and type 4 (M₁ and M₄) receptor agonist, to determine if this agent is effective in the treatment of schizophrenia. METHOD: In this pilot study, the authors examined the efficacy of xanomeline on clinical outcomes in subjects with schizophrenia (N=20) utilizing a double-blind, placebo-controlled, 4-week treatment design. Outcome measures included the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, the Brief Psychiatric Rating Scale (BPRS), the Clinical Global Impression (CGI) scale, and a test battery designed to measure cognitive function in patients with schizophrenia. RESULTS: Subjects treated with xanomeline did significantly better than subjects in the placebo group on total BPRS scores and total PANSS scores. In the cognitive test battery, subjects in the xanomeline group showed improvements most robustly in measures of verbal learning and short-term memory function. CONCLUSIONS: These results support further investigation of xanomeline as a novel approach to treating schizophrenia.

Related Articles:

Cholinergic Agonists as Novel Treatments for Schizophrenia: The Promise of Rational Drug Development for Psychiatry

Jeffrey A. Lieberman, Jonathan A. Javitch, and Holly Moore
Am J Psychiatry 2008 165: 931-936. [Full Text] [PDF]

This article has been cited by other articles:

				J. K. Shirey, A. E. Brady, P. J. Jones, A. A. Davis, T. M. Bridges, J. P. Kennedy, S. B. Jadhav, U. N. Menon, Z. Xiang, M. L. Watson, et al. A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning J. Neurosci., November 11, 2009; 29(45): 14271 - 14286. [Abstract] [Full Text] [PDF]

				J. S. Forbey, A. L. Harvey, M. A. Huffman, F. D. Provenza, R. Sullivan, and D. Tasdemir Exploitation of secondary metabolites by animals: A response to homeostatic challenges Integr. Comp. Biol., September 1, 2009; 49(3): 314 - 328. [Abstract] [Full Text] [PDF]

				A. R. Bolbecker, W. P. Hetrick, J. K. Johannesen, B. F. O'Donnell, J. E. Steinmetz, and A. S. Shekhar Secretin Effects on Cerebellar-Dependent Motor Learning in Schizophrenia Am J Psychiatry, April 1, 2009; 166(4): 460 - 466. [Abstract] [Full Text] [PDF]

				J. E. Marlo, C. M. Niswender, E. L. Days, T. M. Bridges, Y. Xiang, A. L. Rodriguez, J. K. Shirey, A. E. Brady, T. Nalywajko, Q. Luo, et al. Discovery and Characterization of Novel Allosteric Potentiators of M1 Muscarinic Receptors Reveals Multiple Modes of Activity Mol. Pharmacol., March 1, 2009; 75(3): 577 - 588. [Abstract] [Full Text] [PDF]

				D. S. JANOWSKY and J. M. DAVIS Antipsychotic Properties of Muscarinic Drugs Am J Psychiatry, January 1, 2009; 166(1): 110 - 110. [Full Text] [PDF]

				N. POMARA Reduction in Muscarinic M1-Mediated Hypercholinergic State and Beneficial Cognitive Effects of Muscarinic Agonists in Schizophrenia Am J Psychiatry, January 1, 2009; 166(1): 111 - 111. [Full Text] [PDF]

				A. SHEKHAR, D. L. McKINZIE, and C. C. FELDER Drs. Shekhar, McKinzie, and Felder Reply Am J Psychiatry, January 1, 2009; 166(1): 113 - 113. [Full Text] [PDF]

				A. SHEKHAR Dr. Shekhar Replies Am J Psychiatry, January 1, 2009; 166(1): 110 - 111. [Full Text] [PDF]

				A. E. Brady, C. K. Jones, T. M. Bridges, J. P. Kennedy, A. D. Thompson, J. U. Heiman, M. L. Breininger, P. R. Gentry, H. Yin, S. B. Jadhav, et al. Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 941 - 953. [Abstract] [Full Text] [PDF]

				C. K. Jones, A. E. Brady, A. A. Davis, Z. Xiang, M. Bubser, M. N. Tantawy, A. S. Kane, T. M. Bridges, J. P. Kennedy, S. R. Bradley, et al. Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats J. Neurosci., October 8, 2008; 28(41): 10422 - 10433. [Abstract] [Full Text] [PDF]

				A New Treatment Pathway for Schizophrenia? Journal Watch Psychiatry, August 18, 2008; 2008(818): 2 - 2. [Full Text]

				J. A. Lieberman, J. A. Javitch, and H. Moore Cholinergic Agonists as Novel Treatments for Schizophrenia: The Promise of Rational Drug Development for Psychiatry Am J Psychiatry, August 1, 2008; 165(8): 931 - 936. [Full Text] [PDF]

				C. A. Tamminga Accelerating New Knowledge in Schizophrenia Am J Psychiatry, August 1, 2008; 165(8): 949 - 951. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us